![](/wp-content/uploads/2024/01/Screenshot-2024-01-03-at-4.44.14-PM.png)
$599
Senseonics Provides Implantable CGM Updates; Esperion and Daiichi Sankyo Resolve Litigation; Better Therapeutics and Glooko Partner for AspyreRx
Three cardiometabolic-related news items have been observed: Senseonics announced a series of business updates regarding the company’s implantable CGM sensors (view press release); Esperion and Daiichi Sankyo announced a $125M amendment to their collaboration, which includes a resolution to their commercial dispute (view press release); and Better Therapeutics and Glooko announced a partnership to integrate BT’s AspyreRx digital behavior treatment for T2DM into Glooko’s diabetes management platform (view press release). Below, FENIX provides highlights and insights for the respective news items.